DBCO-mPEG, MW 10,000

DBCO-mPEG (MW 10000) stands out as a polyethylene glycol (PEG) derivative prized for its distinctive properties in bioconjugation settings.

Drug Delivery Systems: Spearheading the realm of drug delivery systems, DBCO-mPEG plays a pivotal role in crafting sophisticated solutions. By binding PEG to therapeutic agents, it enhances solubility and stability, prolonging drug circulation in the bloodstream. This innovative approach boosts drug efficacy while mitigating adverse effects.

Bioconjugation and Protein Labeling: Unleashing its potential in bioconjugation endeavors, DBCO-mPEG serves as a crucial component in attaching proteins, antibodies, or biomolecules to surfaces or proteins. This technique proves invaluable in tailoring targeted therapies, where PEGylation enhances therapeutic attributes and reduces immunogenicity of biologics. The rapid, precise reaction of the DBCO group with azide groups streamlines conjugation processes.

Diagnostic Imaging: Elevating diagnostic imaging to new heights, DBCO-mPEG merges with imaging agents to amplify performance. By binding with PEG, it optimizes the biodistribution and accumulation of imaging agents in target tissues, elevating imaging resolution and sensitivity.

Surface Modification: Embarking on surface modification journeys, DBCO-mPEG finds its niche in diverse biomedical and industrial applications. It furnishes a hydrophilic, non-fouling surface, ideal for constructing biocompatible coatings on medical devices and implants. This transformative feature curbs protein and cell adhesion, mitigating risks of complications like infection or thrombosis.